Drug intelligence / Profile preview

AVR-84

Development stage: Preclinical
Lead developer: AyuVis Research
Modality: Small Molecules

Overview

AVR-84 is a small molecule immunomodulator targeting Toll-like receptor 4 (TLR4), currently under development by AyuVis Research. It is specifically designed for the treatment of soft tissue and skin infections, with a focus on those caused by multi-drug resistant (MDR) bacteria. The compound aims to modulate the innate immune system's response to pathogens, potentially enhancing the body's ability to clear bacterial infections while controlling inflammatory damage. AVR-84 is part of AyuVis's broader platform of proprietary TLR modulators intended to address significant unmet needs in infectious and inflammatory diseases.

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on AVR-84.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVR-84.

Explore the full profile